{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:03:32Z","timestamp":1777100612328,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jhep.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:13:05Z","timestamp":1718716385000},"page":"819-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-3041","authenticated-orcid":false,"given":"Pierluigi","family":"Toniutto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmondo","family":"Falleti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Cmet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarosa","family":"Cussigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Degasperi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6901-5575","authenticated-orcid":false,"given":"Maria Paola","family":"Anolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Sambarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-4744","authenticated-orcid":false,"given":"Floriana","family":"Facchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-1256","authenticated-orcid":false,"given":"Riccardo","family":"Perbellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Monico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.06.013_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","author":"Polaris Observatory","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"Fattovich","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.06.013_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A\u00a0phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.06.013_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFNalpha for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.06.013_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2023.04.027","article-title":"No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta","volume":"79","author":"Hollnberger","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib7","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.06.013_bib8","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/0016-5085(94)90821-4","article-title":"In situ localization of the hepatocytic Na+\/Taurocholate cotransporting polypeptide in rat liver","volume":"107","author":"Stieger","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.06.013_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/trf.12516","article-title":"High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center","volume":"54","author":"Zhang","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.jhep.2024.06.013_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/gtmb.2013.0491","article-title":"Association of genetic variation of sodium taurocholate cotransporting polypeptide with chronic hepatitis B virus infection","volume":"18","author":"Li","year":"2014","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.jhep.2024.06.013_bib11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","article-title":"The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B","volume":"65","author":"Hu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.06.013_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12885-016-2257-6","article-title":"A\u00a0genetic variant of the NTCP gene is associated with HBV infection status in a Chinese population","volume":"16","author":"Yang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2024.06.013_bib13","article-title":"Comprehensive assessment showed no associations of variants at the SLC10A1 locus with susceptibility to persistent HBV infection among Southern Chinese","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.06.013_bib14","doi-asserted-by":"crossref","first-page":"105407","DOI":"10.18632\/oncotarget.22211","article-title":"Genetic variations of NTCP are associated with susceptibility to HBV infection and related hepatocellular carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2024.06.013_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Asociacion Latinoamericana para el Estudio del H. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2022.03.014","article-title":"The relationship between NTCP gene varieties and the progress of liver disease after HBV infection: an updated systematic review and meta-analysis","volume":"364","author":"He","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jhep.2024.06.013_bib18","first-page":"1","article-title":"IL-18 and CD14 variants in chronic HBV predisposition: a case-control study with in silico analyses focused on transcription and splicing","author":"Sarhadi","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.jhep.2024.06.013_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00281-022-00935-7","article-title":"Bile acids and their receptors: modulators and therapeutic targets in liver inflammation","volume":"44","author":"Bertolini","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhep.2024.06.013_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/jvh.13831","article-title":"Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA","volume":"30","author":"Deterding","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2024.06.013_bib21","article-title":"Treating hepatitis D with bulevirtide - real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.jhep.2024.06.013_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2022.12.023","article-title":"A 3-year course of bulevirtide monotherapy may cure Hdv infection in cirrhotics","volume":"78","author":"Anolli","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib23","series-title":"Virologica non response with Bulevirtide treatment is not associated with viral resistance or NTCP polymorphisms at week 96","author":"Wedemeyer","year":"2024"},{"key":"10.1016\/j.jhep.2024.06.013_bib24","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.01.035","article-title":"Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies","volume":"80","author":"Allweiss","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.06.013_bib25","article-title":"Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations","volume":"6","author":"Shekhtman","year":"2024","journal-title":"JHEP Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824023195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824023195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:59:34Z","timestamp":1773457174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824023195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0168827824023195"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.013","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}